Welcome to our dedicated page for Werewolf Therapeutics news (Ticker: HOWL), a resource for investors and traders seeking the latest updates and insights on Werewolf Therapeutics stock.
Werewolf Therapeutics, Inc. (Nasdaq: HOWL) is a groundbreaking biopharmaceutical company specializing in the development of innovative cancer treatments. Leveraging its proprietary PREDATOR™ platform, Werewolf Therapeutics is at the forefront of creating conditionally activated therapeutics designed to stimulate the body’s immune system to combat cancer.
Founded with the mission to address the limitations of conventional proinflammatory immune therapies, Werewolf's core offering includes the pioneering INDUKINE™ molecules. These molecules are engineered to remain inactive in peripheral tissues and activate only within the tumor microenvironment (TME), thereby enhancing both adaptive and innate immunity. This strategic approach aims to significantly reduce systemic toxicity while maximizing therapeutic efficacy.
Among its leading developments, the WTX-124 and WTX-330 stand out. WTX-124, an IL-2 INDUKINE molecule, is currently undergoing a Phase 1/1b clinical trial for patients with advanced or metastatic solid tumors. Recent preliminary data presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting highlight WTX-124’s potential, showing it to be well-tolerated and effective even at higher doses. The study demonstrated proof of mechanism and concept with early evidence of monotherapy antitumor activity.
Moreover, Werewolf is exploring the combination of WTX-124 with pembrolizumab (KEYTRUDA®) to expand its therapeutic reach. Another notable candidate, WTX-330, targets both advanced solid tumors and non-Hodgkin lymphoma using IL-12 INDUKINE molecules.
In addition to its clinical advancements, Werewolf Therapeutics has been actively presenting preclinical data supporting the efficacy of its INDUKINE technology. At recent conferences, the company introduced WTX-518, a novel IL-18 INDUKINE molecule, and reported on the preclinical development of IL-10 INDUKINE molecules for treating inflammatory bowel disease.
With a consistent track record of innovation and a robust pipeline of transformative therapies, Werewolf Therapeutics continues to make significant strides towards providing new hope for cancer patients worldwide.
Werewolf Therapeutics (Nasdaq: HOWL) announced the publication of preclinical data for its lead molecule WTX-124 in Cancer Immunology Research. The study shows that WTX-124, a conditionally activated Interleukin-2 (IL-2) molecule, delivers IL-2 selectively to tumor environments, enhancing anti-tumor immune responses. Key findings include improved therapeutic window, activation of T cells and NK cells, and stability in human serum. The company plans to file an IND application for WTX-124 in the first half of 2022 and is collaborating with Merck to assess its efficacy in patients with solid tumors.
Werewolf Therapeutics (Nasdaq: HOWL) has announced the publication of two abstracts for presentations at the American Association for Cancer Research (AACR) Annual Meeting, occurring from April 8-13, 2022, in New Orleans. The abstracts focus on two innovative treatment candidates, WTX-124 and WTX-330, designed to activate the immune system against tumors. Both presentations will be held on April 11, highlighting their potential to enhance anti-tumor immunity. E-posters will be available starting April 8 and accessible to registered attendees until July 13.
Werewolf Therapeutics, Inc. (Nasdaq: HOWL), a biopharmaceutical innovator specializing in immune-stimulating cancer therapeutics, announced its participation in the SVB Leerink Global Healthcare Conference from February 14-18, 2022. The company’s CEO, Daniel J. Hicklin, will present on February 16 at 3:40PM EDT. A webcast link will be provided, and a replay will be available for 30 days post-presentation. Werewolf's proprietary PREDATOR™ platform focuses on creating conditionally activated molecules, including its leading candidates WTX-124 and WTX-330, targeting solid tumors.
Werewolf Therapeutics, Inc. (Nasdaq: HOWL) announced its participation in the virtual H.C. Wainwright Bioconnect Conference from January 10-13, 2022. CEO Daniel J. Hicklin, Ph.D., will present an overview of the company on-demand starting January 10 at 7 a.m. EST. Werewolf is focused on developing conditionally activated therapeutics that enhance the immune system for cancer treatment, utilizing its proprietary PREDATOR™ platform. The company's lead candidates, WTX-124 and WTX-330, target tumor microenvironments while minimizing peripheral activation.
Werewolf Therapeutics (Nasdaq: HOWL) announced its inclusion in the Nasdaq Biotechnology Index (NBI), effective December 20, 2021. The NBI measures the performance of biotechnology and pharmaceutical securities on the Nasdaq Stock Market. Companies in the index must meet strict eligibility criteria, enhancing Werewolf's visibility in the market. Werewolf focuses on conditionally activated therapeutics to boost the immune response against cancer, leveraging its PREDATOR™ platform and developing INDUKINE™ molecules, including WTX-124 and WTX-330, for solid tumor treatment.
Werewolf Therapeutics (Nasdaq: HOWL) announced promising preclinical data on its INDUKINE molecules, IL-12 and IFNα, which inhibited lymphoma tumor growth in mice and showed tolerability in non-human primates. These results will be presented at the 63rd American Society of Hematology Annual Meeting on December 12, 2021. The studies suggest that these therapeutics may represent a breakthrough in cancer treatment by enhancing anti-tumor immune responses while reducing adverse effects associated with traditional cytokines.
Werewolf Therapeutics (Nasdaq: HOWL) reported significant advancements in their clinical pipeline, highlighting a collaboration with Merck to assess WTX-124 combined with KEYTRUDA. The company plans to file INDs for WTX-124 and WTX-330 in H1 2022. As of September 30, 2021, cash reserves totaled $170.4 million, a notable increase from $92.6 million at the end of 2020. However, net losses for Q3 2021 were $13.8 million, up from $6.1 million year-over-year. Overall, Werewolf's solid financial position supports its ongoing R&D efforts.
Werewolf Therapeutics (Nasdaq: HOWL), a pioneering biopharmaceutical company, has announced management will present at two key investor conferences this month. The Jefferies Global Healthcare Conference is scheduled for November 18th at 3:00 AM EST, followed by the Evercore ISI HealthCONx Conference on November 30th at 10:30 AM EST. The webcasts will be available on their investor relations webpage. The company aims to advance its innovative INDUKINE™ therapeutics, designed to activate the immune system against cancer, particularly through products WTX-124 and WTX-330.
Werewolf Therapeutics, Inc. (Nasdaq: HOWL) announced the appointment of Meeta Chatterjee, Ph.D., as a new board member. Dr. Chatterjee brings over 30 years of experience in pharmaceutical R&D and business development, previously serving at Legend Biotech Corporation and Merck Research Labs. She aims to enhance the company's strategy as it advances its lead product candidates, WTX-124 and WTX-330, targeting solid tumors. This strategic addition is anticipated to strengthen the board's capabilities during a pivotal time for the company's development.
Werewolf Therapeutics (Nasdaq: HOWL) announced the presentation of promising preclinical data at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), taking place from November 10-14, 2021. This data showcases the potential of their INDUKINE™ molecules, specifically WTX-124 and WTX-330, in enhancing anti-tumor immune responses. The results will be included in IND applications expected to be filed in the first half of 2022. The abstracts will be available on the SITC website starting November 9, 2021.
FAQ
What is the current stock price of Werewolf Therapeutics (HOWL)?
What is the market cap of Werewolf Therapeutics (HOWL)?
What does Werewolf Therapeutics specialize in?
What is the PREDATOR™ platform?
What are INDUKINE™ molecules?
What is WTX-124?
Are there other key product candidates from Werewolf?
What recent advancements has Werewolf made?
How does Werewolf's approach differ from conventional therapies?
Is Werewolf involved in any partnerships or collaborations?
What is the significance of the recent WTX-124 clinical data?
How can investors stay informed about Werewolf's progress?
